Sign in
AC

Albertsons Companies, Inc. (ACI)·Q3 2025 Earnings Summary

Executive Summary

  • Q3 FY2024 (reported Jan 8, 2025) delivered stable topline and strong digital engagement: Net sales rose 1.2% to $18.77B; identical sales +2.0%; digital sales +23%; adjusted EBITDA $1.065B; adjusted EPS $0.71; GAAP EPS $0.69 benefited from an $81M discrete state tax item .
  • Guidance was refined: IDs trimmed to 1.8–2.0% but adjusted EBITDA raised to $3.95–$3.99B and adjusted EPS to $2.25–$2.31; tax rate cut to 15–16% on the discrete tax benefit—overall a positive quality of earnings shift despite modest top-line caution .
  • Strategic highlights/catalysts: dividend increased 25% to $0.15 and a $2.0B buyback authorization announced in December; Q3 call emphasized $1.5B three-year productivity savings and accelerating retail media (AMC) and AI initiatives—key investor focus areas going into FY2025 .
  • Mix headwinds persisted (pharmacy and first‑party e-commerce) compressing gross margin rate by 27 bps ex fuel/LIFO YoY, partially offset by productivity and shrink improvements, setting the stage for margin defense in FY2025 .
  • Near-term watch items: December sector slowdown cited by management; variability in Q4 comps (Super Bowl/Valentine’s timing) and continued margin mix effects from pharmacy/e‑commerce; productivity execution is the swing factor .

What Went Well and What Went Wrong

What Went Well

  • Digital and loyalty momentum: digital sales +23% and loyalty members +15% to 44.3M in Q3; management reiterated omni-platform engagement as a driver of customer lifetime value .
  • Productivity traction/plan: company reiterated a $1.5B savings plan over three years leveraging tech, supply chain automation (WMS, DCs), and operating discipline; “we plan to deliver $1.5 billion in savings…” .
  • Retail media (AMC) growth: “AMC is currently growing faster than the market” with improved measurement and audience targeting—positioned as a reinvestment fuel source .

What Went Wrong

  • Gross margin mix pressure: ex fuel/LIFO gross margin rate −27 bps YoY as pharmacy and first‑party e‑commerce mix grew; picking/delivery costs also weighed on margins .
  • SG&A rate up YoY: selling & administrative expenses rose to 25.1% of revenue (ex fuel +6 bps), driven by merger-related and occupancy/security costs .
  • Cautious consumer/macro: management trimmed the top end of IDs, citing a broad December slowdown in food & beverage and a tighter holiday calendar; “food and beverage sector slowed down broadly” .

Financial Results

Year-over-Year (Q3 FY2023 vs Q3 FY2024)

MetricQ3 FY2023Q3 FY2024
Net sales and other revenue ($USD Millions)$18,557.3 $18,774.5
Gross margin (%)28.0% 27.9%
Selling & Administrative (%)24.8% 25.1%
Adjusted EBITDA ($USD Millions)$1,106.5 $1,065.1
GAAP Diluted EPS ($)$0.62 $0.69
Adjusted Diluted EPS ($)$0.79 $0.71
Identical Sales (%)—2.0%

Sequential Trend (Oldest → Newest: Q3 FY2024, Q1 FY2025, Q2 FY2025)

MetricQ3 FY2024 (12w, Nov 30, 2024)Q1 FY2025 (16w, Jun 14, 2025)Q2 FY2025 (12w, Sep 6, 2025)
Net sales & other revenue ($MM)$18,774.5 $24,880.8 $18,915.8
Adjusted EBITDA ($MM)$1,065.1 $1,111.0 $848.4
Adjusted Diluted EPS ($)$0.71 $0.55 $0.44
Gross margin (%)27.9% 27.1% 27.0%
Selling & Admin (%)25.1% 25.4% 25.4%
Identical Sales (%)2.0% 2.8% 2.2% (adjusted)

KPIs

KPIQ3 FY2024Q1 FY2025Q2 FY2025
Digital sales growth YoY (%)+23% +25% +23%
Loyalty members (Millions)44.3 47.3 48.7
E‑commerce penetration of grocery>7% (company-wide) Well above 9% (commentary) Well above 9% (commentary)
Pharmacy sales penetration>11% of total annual revenue ——
Net debt ratio (rolling 4Q)1.88x 1.96x 2.02x

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Identical Sales GrowthFY20241.8%–2.2% 1.8%–2.0% Lowered top end
Adjusted EBITDA ($B)FY2024$3.90–$3.98 $3.95–$3.99 Raised
Adjusted EPS ($)FY2024$2.20–$2.30 $2.25–$2.31 Raised
Effective Tax Rate (%)FY2024~23% 15%–16% (reflects $81M discrete benefit) Lowered
Capital Expenditures ($B)FY2024$1.8–$1.9 $1.8–$1.9 Maintained
DividendNext Payment$0.12 (prior) $0.15 (declared Feb 7, 2025) Raised
Share Repurchase AuthorizationOngoing$2.0B (Dec 11, 2024) $2.0B (unchanged in Q3 context) Maintained

Earnings Call Themes & Trends

TopicPrevious Mentions (Q1 FY2025)Previous Mentions (Q2 FY2025)Current Period (Q3 FY2024)Trend
AI/Technology initiativesTech-first; AI agents for pricing/promo; store tools; DC automation “Ask AI” launched; OpenAI partnership for merchandising intelligence AI for misscan prompts/shrink; produce tech; WMS roll-out Accelerating
Supply chain/automationDC automation progress; labor forecasting Automation, WMS; offshore hubs (India/Manila) 30% DC volume automated and WMS fully implemented by end of 2025 Progressing
Tariffs/macro90% domestic sourcing; limited near-term impact 90% domestic; proactive mitigation December slowdown across sector; cautious consumer Cautious
Pharmacy & GLP‑1+20% pharmacy; GLP‑1 ~half of comp; valuable customers; working on profitability +19% pharmacy; central fill; scaling services; near break-even e‑comm >11% penetration; GLP‑1 growth; contribution margin negative; leveraging cross-shop Strong but dilutive
Retail media (AMC)Outpacing industry; building inventory & measurement Improved ROAS; full-funnel; off-site integrations “Growing faster than market”; partnerships planned Building
Pricing/value strategySurgical price investments; own brands emphasis Incremental shelf price investments; unit inflection Strategic price in select categories/markets; productivity funding Ongoing
Shrink/store operationsShrink favorability via self-checkout tech —Shrink improvement continues; AI/self-checkout Improving
Store footprint—Closures/openings; optimizing assets Real estate “hygiene”; more closures near term; selective openings Optimization
Capital allocation$315M repurchases Q1 $750M ASR; dividend $0.15 Dividend +25% to $0.15; $2.0B buyback authorization Increasing returns

Management Commentary

  • “Over the next 3 years, we plan to deliver $1.5 billion in savings to invest in our customer value proposition and growth initiatives as well as to offset inflationary headwinds.”
  • “AMC… is currently growing faster than the market… we will continue to invest in delivering consistent omni execution for brand campaigns across our digital and physical assets.”
  • “Our e‑commerce business… has driven sales penetration to over 7% of grocery revenue, with our top performing market over 9%.”
  • “Q3 ’24 adjusted EBITDA was $1.065 billion… adjusted EPS was $0.71 per diluted share… we increased our quarterly dividend by 25% to $0.15 per share.”
  • “December has been kind of a little wonky… the food and beverage sector overall sequentially slowed down… we just wanted to be cautious.”

Q&A Highlights

  • Guidance cadence: IDs trimmed given December slowdown; EBITDA/EPS raised via productivity and tax benefit; Q4 variability driven by major events (Super Bowl, Valentine’s) timing and mix .
  • Margin mix: Pharmacy and e‑commerce growth dilute gross margin; productivity and shrink mitigate; similar drivers expected into Q4/FY2025 .
  • Competitive landscape: Management highlighted mass and club retailers “growing much faster” and the need to sharpen pricing selectively while maintaining service/value proposition .
  • Productivity detail: Mix of quick wins (offshoring, buying scale) and longer-horizon initiatives; steady “drumbeat” expected over the 3‑year window .
  • Retail media outlook: Platform/inventory now in place; expect material contribution over ~3 years; omni execution and partnerships emphasized .

Estimates Context

  • Wall Street consensus (S&P Global) for Q3 FY2024 EPS and revenue was not retrievable at the time of analysis due to SPGI rate limits; therefore, explicit beat/miss versus consensus is unavailable.
  • Implications: With modest IDs and known mix headwinds, consensus likely focused on EBITDA/EPS quality and the tax-rate-driven GAAP EPS lift; productivity trajectory remains the key driver for estimate revisions. (SPGI consensus unavailable)

Key Takeaways for Investors

  • Mix matters: Continued pharmacy/e‑commerce strength supports share and CLV but weighs on gross margin rate; track productivity and shrink to offset margin dilution .
  • Guidance quality improved: Despite trimming IDs, management raised adjusted EBITDA/EPS and lowered the tax rate—focus on sustained cost discipline and cash conversion through FY2024/FY2025 .
  • Capital returns are stepping up: Dividend to $0.15 and $2.0B buyback authorization provide support; watch execution pace relative to leverage target (~1.9–2.0x rolling) .
  • Retail media and AI are medium-term levers: AMC growth faster than market and broad AI deployment should enhance monetization and productivity—monitor tangible revenue/EBITDA contribution ramp over the next 6–12 quarters .
  • Supply chain automation is a 2025 catalyst: 30% automated DC volume and company-wide WMS roll-out by end 2025 should drive in-stock quality and cost-to-serve improvements—key to margin defense .
  • Near-term trading setup: December slowdown and Q4 event timing create comp variability; operating execution, mix management, and productivity updates could be stock catalysts at the next call .
  • Competitive response: Selective price investments and higher own brand penetration (toward 30%) are intended to protect share vs mass/club—watch unit trajectory and category-level elasticity effects through FY2025 .

Appendix: Other Relevant Press Releases (Q3 context)

  • Dividend Declaration: Board declared $0.15 per share payable Feb 7, 2025 (raised from $0.12) .
  • Share Repurchase Authorization: Board authorized up to $2.0B common stock repurchases (Dec 11, 2024) .
  • Merger termination and litigation: Merger terminated following injunctions; Company seeking damages and $600M termination fee; details in Q3 10‑Q/8‑K .